Mianserin and depression, anxiety, insomnia Case report
Article Sidebar
Published:
Mar 31, 2022
Keywords:
mianserin, insomnia, depression, anxiety disorders, mood disorders, outpatient treatment
Main Article Content
Abstract
Mianserin is a drug that has been used for many years to reduce symptoms of depression such as depression, anxiety and insomnia. Which seriously impair the functioning of the patient and, if are untreated, may lead to recurrence of depression. A beneficial feature of the drug is its low potential for adverse interactions with other drugs. For this reason, using of mianserin should be considered in the elderly and patients with comorbidities.
Article Details
How to Cite
Gładka , A., & Rymaszewska , J. (2022). Mianserin and depression, anxiety, insomnia. Medycyna Faktow (J EBM), 15(1(54), 109-113. https://doi.org/10.24292/01.MF.0122.15
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017; 27: 101-11. http://doi.org/10.1016/j.ajp.2017.01.025.
2. Asarnow LD, Manber R. Cognitive Behavioral Therapy for Insomnia in Depression. Sleep Med Clin. 2019; 14(2): 177-84. http://doi.org/10.1016/j.jsmc.2019.01.009.
3. Protti M, Mandrioli R, Marasca C et al. New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Med Res Rev. 2020; 40(5): 1794-832.
4. Sacre S, Jaxa-Chamiec A, Low CMR et al. Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors. Front Immunol. 2019; 10: 1167. http://doi.org/10.3389/fimmu.2019.01167.
5. Charakterystyka produktu leczniczego Deprexolet.
6. Bazire S. Przewodnik leków psychotropowych 2018. Lloyd-Reinhold Publications Limited. Stephen Bazire 2020.
7. Pinder RM, Fink M. Mianserin. Mod Probl Pharmacopsychiatry. 1982; 18: 70-101. http://doi.org/10.1159/000406237.
8. Kennedy SH, Lam RW, McIntyre RS et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016. Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. The Canadian Journal of Psychiatry.
9. Gabriel FC, de Melo DO, Fráguas R et al. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One. 2020; 15(4): e0231700. http://doi.org/10.1371/journal.pone.0231700.
10. Riblet N, Larson R, Watts BV et al. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry. 2014; 36(5): 466-73. http://doi.org/10.1016/j.genhosppsych.2014.05.010.
11. Sobańska A, Wichniak A, Wierzbicka A et al. Mianseryna w leczeniu bezsenności pierwotnej. Sen. 2006; 6(2): 58-63.
12. Palomäki H, Berg A, Meririnne E et al. Complaints of poststroke insomnia and its treatment with mianserin. Cerebrovasc Dis. 2003; 15(1-2): 56-62. http://doi.org/10.1159/000067127.
13. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54. http://doi.org/10.1017/S1461145713000667.
14. Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003; 13: 123-8. http://doi.org/10.1016/S0924-977X(02)00155-4.
15. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011; 33(3): 484-92. http://doi.org/10.1007/s11096-011-9507-0.
2. Asarnow LD, Manber R. Cognitive Behavioral Therapy for Insomnia in Depression. Sleep Med Clin. 2019; 14(2): 177-84. http://doi.org/10.1016/j.jsmc.2019.01.009.
3. Protti M, Mandrioli R, Marasca C et al. New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Med Res Rev. 2020; 40(5): 1794-832.
4. Sacre S, Jaxa-Chamiec A, Low CMR et al. Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors. Front Immunol. 2019; 10: 1167. http://doi.org/10.3389/fimmu.2019.01167.
5. Charakterystyka produktu leczniczego Deprexolet.
6. Bazire S. Przewodnik leków psychotropowych 2018. Lloyd-Reinhold Publications Limited. Stephen Bazire 2020.
7. Pinder RM, Fink M. Mianserin. Mod Probl Pharmacopsychiatry. 1982; 18: 70-101. http://doi.org/10.1159/000406237.
8. Kennedy SH, Lam RW, McIntyre RS et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016. Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. The Canadian Journal of Psychiatry.
9. Gabriel FC, de Melo DO, Fráguas R et al. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One. 2020; 15(4): e0231700. http://doi.org/10.1371/journal.pone.0231700.
10. Riblet N, Larson R, Watts BV et al. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry. 2014; 36(5): 466-73. http://doi.org/10.1016/j.genhosppsych.2014.05.010.
11. Sobańska A, Wichniak A, Wierzbicka A et al. Mianseryna w leczeniu bezsenności pierwotnej. Sen. 2006; 6(2): 58-63.
12. Palomäki H, Berg A, Meririnne E et al. Complaints of poststroke insomnia and its treatment with mianserin. Cerebrovasc Dis. 2003; 15(1-2): 56-62. http://doi.org/10.1159/000067127.
13. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54. http://doi.org/10.1017/S1461145713000667.
14. Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003; 13: 123-8. http://doi.org/10.1016/S0924-977X(02)00155-4.
15. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011; 33(3): 484-92. http://doi.org/10.1007/s11096-011-9507-0.